Mission Wealth Management’s Royalty Pharma RPRX Stock Holding History

Mission Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Buy	+3,784	New	+$197K	﹤0.01%	1012

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mission Wealth Management's RPRX Position: Q2 2026 in Review

Mission Wealth Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 3,784 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1012 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Mission Wealth Management held 3,784 shares of Royalty Pharma worth $212K as of Q2 2026.
Royalty Pharma was a new Mission Wealth Management position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Mission Wealth Management's portfolio in Q2 2026, its #1012 holding.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.